losartan
Selected indexed studies
- Clinical pharmacokinetics of losartan. (Clin Pharmacokinet, 2005) [PMID:16029066]
- Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma. (Clin Cancer Res, 2022) [PMID:34580111]
- Hyperuricemia and Gout: The Role of Losartan. (Sr Care Pharm, 2023) [PMID:37612850]
_Worker-drafted node — pending editorial review._
Connections
losartan is a side effect of
Sources
- Clinical pharmacokinetics of losartan. (2005) pubmed
- Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma. (2022) pubmed
- Hyperuricemia and Gout: The Role of Losartan. (2023) pubmed
- Topical Losartan in the Management of Corneal Scarring Fibrosis: Update on Dosage, Efficacy, and Potential Epithelial Toxicity. (2025) pubmed
- Topical Losartan in the Treatment of Stromal Scarring After Refractive Surgery. (2025) pubmed
- Losartan: Comprehensive Profile. (2015) pubmed
- Losartan in diabetic nephropathy. (2003) pubmed
- [Losartan]. (1997) pubmed
- Losartan: a review of its use, with special focus on elderly patients. (2000) pubmed
- Pharmacokinetic evaluation of losartan. (2011) pubmed